Kirsten Axelsen (she/her)

Healthcare consultant, summited Kilimanjaro on team Timmerman @climbtofight, Fellow @AspenInstitute

[DLA Piper @DLA_Piper]

As some #IRA provisions take effect for the first time in 2025, a DLA Piper assessment of how the number and types of #Medicare plans changed over the last three years poses potential considerations for policy makers: https://t.co/iV9jmmZ0Uj

#LifeSciences #Insurance #Healthcare

[INCUBATE @incub8coalition]

Join Incubate and @DLA_Piper during #JPM2025 for a #biopharma and #healthpolicy panel featuring @nkjellson, @kjacny, @johnbstanford, and Gaurav Gupta. RSVP here: https://t.co/JnkGY1lbWe

[Kirsten Axelsen (she/her) @kjacny]

Coverage of Obesity Medications Can Make America Healthier (Again) https://t.co/Qf1wXEFauJ

[Kirsten Axelsen (she/her) @kjacny]

The IRA And Post-Approval Clinical Research For Cancer Medicines https://t.co/6ZBqdYPHOY

[Health Affairs @Health_Affairs]

There is a pressing need for robust evidence to inform biopharmaceutical policy, @kjacny and co-authors write in Health Affairs Scholar.

The article is part of a new series that explores financial rewards for new drugs and R&D investment. @ITIFdc

https://t.co/amnZiWb1om

[Kirsten Axelsen (she/her) @kjacny]

If we import other countries' drug policy we also import their outcomes ...
https://t.co/EZV3l1YZs8

[Kirsten Axelsen (she/her) @kjacny]

@Frank_S_David I appreciate you pointing out the transparency of methods... important to do in policy research

[Frank S. David @Frank_S_David]

Excited to read this analysis of the IRA’s potential impact on cancer drug R&D — including the detailed, transparent methods! https://t.co/VHIhxBsfnX

[Kirsten Axelsen (she/her) @kjacny]

Price controls on medicines save money for the federal government, but not necessarily for consumers https://t.co/NZxfAVXYdu

[Kirsten Axelsen (she/her) @kjacny]

Join me on 5/23 for a @KFF virtual conversation on what the Biden Administration could do to address drug affordability.
With other experts, we’ll explore the drivers of rising prescription drug prices and potential administrative actions to address them. https://t.co/nX5ULr8bZB

[Kirsten Axelsen (she/her) @kjacny]

https://t.co/Ft0nblvWlg

[Kirsten Axelsen (she/her) @kjacny]

@tigerlilycares @thatsdaria @archieallela @Maimah making sure everyone has insurance is a start, expand Medicaid where it hasn't been, require no cost sharing for detection beyond mammograph (eg MRI) for high risk women #TLCtransform

[Kirsten Axelsen (she/her) @kjacny]

@tigerlilycares @Maimah @thatsdaria @archieallela CDC requires each state to publish a CCC targeted to their population, many states have mammography goals over 50 in a six state analysis only 1 had a goal to improve younger screening #TLCTransform

[Kirsten Axelsen (she/her) @kjacny]

@tigerlilycares @Maimah earlier screening (directed through guidelines) could reduce disparities in outcomes between white and Black women by 57% #TLCTransform

[Kirsten Axelsen (she/her) @kjacny]

@tigerlilycares @Maimah Some groups do American College of Radiology and the Society of Breast Imaging, federal guidelines permit younger screening but don't recommend #TLCtransform

[Kirsten Axelsen (she/her) @kjacny]

@Maimah @tigerlilycares agreed, the National Early Detection Program only reaches 11% of eligible women, Comprehensive Cancer Control plans could have metrics for TNBC detection in at risk populations

[Kirsten Axelsen (she/her) @kjacny]

@tigerlilycares @Maimah @thatsdaria @archieallela American College of Radiology and Breast Imaging Guidelines call for heighted screening for Black women, should elevate to federal guidelines #tlctransform

[Kirsten Axelsen (she/her) @kjacny]

@tigerlilycares @thatsdaria @Maimah @archieallela yet data is not collected broadly at state or federal level that measures subtype, need credible evidence and tracking #tlctransform

[Kirsten Axelsen (she/her) @kjacny]

@tigerlilycares Black women 2x as likely have TNBC vs white women, if only mammograms are available for women over 50 then Black women are less likely to get screened and treated appropriately => less equity in outcomes